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The TOR kinase has emerged as a central regulator of cellular
responses to such diverse environmental stress as amino acid
starvation, hypoxia, and growth factor deprivation (Bjornsti and
Houghton, 2004; Schmelzle and Hall, 2000). Under stress con-
ditions, TOR signaling is suppressed, which leads to cell cycle
arrest. Thus, TOR acts as a gatekeeper, preventing cells from
progressing from G1 phase and initiating DNA replication under
suboptimal growth conditions. Indeed, TOR may be in a path-
way parallel to p53 in controlling cell cycle transit and replica-
tion. However, if TOR plays a role analogous to p53, is this
restricted to cell cycle regulation, or, like p53, does the TOR
pathway also regulate apoptosis? Several recent findings
(Ruggero et al., 2004; Wendel et al., 2004), including the
Avdulov et al. (2004) paper in this issue, establish that TOR sig-
naling also regulates apoptosis and plays an important role in
tumorigenesis.
In the yeast Saccharomyces cerevisiae, the TOR signaling
pathway directly or indirectly controls many aspects of cellular
metabolism, including translation initiation, protein turnover,
and transcription. Many of these pathways have been main-
tained in mammalian cells (Bjornsti and Houghton, 2004).
Increasing evidence places TOR as a central regulator of cell
growth (size), proliferation, and, more recently, survival (Figure
1). In response to mitogen stimulation, mammalian TOR regu-
lates translation initiation through two distinct pathways:
(1) phosphorylation and activation of ribosomal p70 S6 kinase
(S6K1), and (2) cap-dependent translation via eukaryotic initia-
tion factor 4E (eIF4E), which binds the 7me GpppN cap of
mRNA and directs the correct positioning of ribosomal subunits
to initiate translation. In the latter case (Figure 2), TOR directly
phosphorylates the 4E binding protein (4E-BP1, the suppressor
of eIF4E), causing its dissociation from eIF4E. eIF4E then binds
eIF4G, promoting the assembly of the eIF4F initiation complex.
It has been recognized for some time that dysregulation of
this pathway, either proximal or distal to TOR, occurs in many
human cancers, implicating aberrant signaling in the genesis
and maintenance of the transformed phenotype (reviewed by
Bjornsti and Houghton, 2004; Harris and Lawrence, 2003; Luo
et al., 2003; Vivanco and Sawyers, 2002). For example, onco-
genes, such as Ras or activated growth factor receptors, upreg-
ulate PI3K signaling (Figure 1). Human cancers frequently
harbor activating mutations in the p110 catalytic subunit of PI3K
or genomic amplification of sequences encoding the down-
stream kinase, Akt2. Normally, the dual function phosphatase
PTEN negatively regulates Akt. However, PTEN activity is atten-
uated in many tumors through deletion, silencing, or mutation,
resulting in constitutive activation of TOR-dependent pathways.
Activated Akt also promotes survival under conditions of cellular
stress. This antiapoptotic effect is, in part, mediated by direct
phosphorylation or alterations in the translation of apoptotic
regulators and decreased transcription of proapoptotic genes,
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antiapoptotic signaling. Mutations downstream of Akt that activate the TOR kinase are found in tumor-prone syndromes, while
overexpression of translation initiation complex components, such as eIF4E, occurs frequently in human cancer. However,
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fers malignant characteristics and induces cancer by suppressing apoptosis, underscoring the potential of therapeutics that
selectively target the Akt-TOR-eIF4E pathway.
Figure 1. Regulation of TOR signaling and translation initiation by TOR
Activation of TOR, by PI-3K-Akt signaling, regulates translation through two
independent pathways, S6K1 and eIF4E.
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possibly via inhibition of forkhead transcription factors.
Mutations downstream of Akt that lead to activation of TOR
are also associated with cancer-prone syndromes such as
tuberous sclerosis (TSC) and Peutz-Jeghers syndrome
(Cheadle et al., 2000; Woods et al., 2003). The TSC complex
negatively regulates TOR by inhibiting a small GTP binding pro-
tein, Rheb, considered to be the direct activator of TOR (Stocker
et al., 2003; Tee et al., 2003; Zhang et al., 2003). Mutation or
loss of heterozygosity in the components of the TSC complex
gives rise to TSC syndrome (Cheadle et al., 2000). While inacti-
vation of TSC may not lead to malignancy per se, deregulation
of this pathway is associated with
increased risk of developing malignant
renal carcinoma of clear cell histology
and appears critical for angiogenesis in
developing malignancies. The latter is
consistent with the observation that
TSC2 regulates vascular endothelial
growth factor (VEGF) through TOR-
dependent and -independent pathways
(Brugarolas et al., 2003). The overex-
pression or activating mutation of TOR in
human cancer has not been reported.
Nevertheless, the observations that TSC
mutations predispose to malignant trans-
formation, while Rheb is overexpressed
in transformed cells (Gromov et al.,
1995), suggest that activation of Akt per
se is not the whole story. Rather, events
downstream of Akt may also be critical
for development of malignancies.
Each of the alterations in signaling,
discussed above, activates TOR, which
in turn controls initiation of translation
through two independent pathways,
S6K1 and 4E-BP-eIF4E. However, a
large body of data indicates that the dys-
regulation of cap-dependent translation
via alterations in 4E-BP-eIF4E pathway,
rather than activation of S6K1, is associ-
ated with human cancer (Bjornsti and
Houghton, 2004). For instance, the RNA
cap binding protein (eIF4E), considered
to be the rate-limiting step in formation of the eIF4F initiation
complex, is overexpressed in multiple human cancers, and
advanced stage disease is often characterized by genomic
amplification (Bjornsti and Houghton, 2004; De Benedetti and
Harris, 1999). Moreover, several lines of evidence suggest that
increased expression of eIF4E is oncogenic. Overexpression of
eIF4E alone, or in combination with v-myc and E1A, transforms
rat embryo fibroblasts (Lazaris-Karatzas and Sonenberg,
1992), while microinjection of eIF4E is mitogenic in NIH 3T3
cells and is dependent upon Ras signaling (Lazaris-Karatzas et
al., 1992). Cells transformed by chemical mutagenesis, onco-
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Figure 2. TOR control of cap-dependent
translation
A: TOR phosphorylates 4E-BP, allowing the RNA
cap binding protein eIF4E to associate with the
scaffold protein eIF4G and establish the eIF4F
initiation complex.
B: Rapamycin inhibits cap-dependent transla-
tion by inhibiting mTOR-dependent phosphory-
lation of 4E-BP. Hypophosphorylated 4E-BP
binds eIF4E, thereby preventing eIF4E binding to
eIF4G.
C: Increased eIF4E, with or without decreased
4E-BP, is associated with oncogenesis, progres-
sion in many human malignancies, and
rapamycin resistance.
D: Intrinsic and acquired resistance to
rapamycin is associated with decreased
expression of 4E-BP1, the suppressor of eIF4E,
and increased anchorage-independent prolif-
eration.
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genes, or viruses frequently exhibit increased transcription of
eIF4E and eIF2α, another component of eIF4F (Graff et al.,
1995; Miyagi et al., 1995; Rinker-Schaeffer et al., 1993;
Rosenwald, 1996). In squamous cell carcinoma of the lung, the
eIF4G scaffold protein is overexpressed (Bauer et al., 2002). In
contrast, alterations in S6K1 in human cancer are rare (Bjornsti
and Houghton, 2004).
Thus, dysregulation of translation initiation may result from
activation of upstream effectors of TOR signaling and/or overex-
pression of components of the translation machinery, such that
cap-dependent translation is no longer regulated in a TOR-
dependent manner. A role for TOR signaling in maintaining the
transformed phenotype has previously been suggested
(Nomura et al., 2003); however, a causal relationship between
constitutive activation of TOR signaling and transformation is
more clearly established in several recent papers. The study by
Avdulov et al. (2004) implicates TOR signaling in maintaining
cap-dependent translation as a critical component in suppress-
ing apoptosis and in maintaining the tumorigenic phenotype.
They show that in normal human mammary epithelial cells
(HMECs), cap-dependent translation is suppressed. eIF4E-
Cap-bound complexes contained predominantly 4E-BP1,
whereas those isolated from carcinoma cells contained pre-
dominantly eIF4G, indicating formation of an active eIF4F initia-
tion complex only in cancer cells. Importantly, under serum-free
conditions, increased eIF4F was associated with decreased
apoptosis, thus implying that TOR signaling to eIF4E functions
as a survival pathway, in agreement with previous studies
(Hosoi et al., 1999; Huang et al., 2003). Of note is that tumor
cells most resistant to serum-withdrawal-induced apoptosis
maintained 4E-BP1 phosphorylation (as would be anticipated
for cells with activating mutations upstream of TOR).
Forced overexpression of eIF4E in HMECs increased
clonogenic potential, conferred anchorage-independent growth
in soft agar, and reduced apoptosis. All of these effects were
reversed by overexpression of 4E-BP1, confirming that malig-
nant characteristics are induced by dysregulated cap-depen-
dent translation. As diagrammed in Figure 2, whether these
phenotypes are a consequence of increased eIF4E, or result
from changes in the stoichiometry of eIF4E:4E-BP1, which
would abrogate TOR control of cap-dependent translation,
remains to be ascertained. Along these lines, downregulation of
4E-BP1, which is characteristic of normal or malignant myo-
genic cells selected for acquired resistance to rapamycin (a
specific inhibitor of TOR signaling), is accompanied by
increased c-MYC levels and increased anchorage-independent
growth (Dilling et al., 2002).
Avdulov et al. (2004) provide additional evidence consis-
tent with the idea that restoring control of cap-dependent trans-
lation in cancer cells leads to apoptosis. In these studies,
overexpressing phosphorylation site mutants of 4E-BP1 (which
constitutively bind eIF4E and thereby preclude formation of the
eIF4F initiation complex) induced apoptosis of both MDA-MB-
231 and MDA-MB-468 breast carcinoma cells. Expression of
these 4E-BP1 mutants decreased cell cycle transit, consistent
with previous studies (Jiang et al., 2003), and reduced anchor-
age-independent growth.These data clearly implicate dysregu-
lation of eIF4F-dependent translation in conferring the
malignant phenotype in normal epithelial cells and in the main-
tenance of such phenotypes in cancer cells in culture.
Importantly, these results also extended to in vivo models,
where overexpression of wild-type and phosphorylation-defec-
tive mutant forms of 4E-BP1 inhibited the tumorigenicity of
breast carcinoma cell lines in athymic nude mice. Notably, in
tumor cells overexpressing wild-type 4E-BP1, apoptosis
increased from 2% to a maximum of 14%, and the S phase
fraction decreased slightly. These findings indicate that modest
changes in cell proliferation and cell death suffice to prevent
tumor formation. Of interest is that expression of a 4E-BP1
phosphorylation mutant led to early apoptosis. In those tumors
that developed, the loss of mutant protein expression is consis-
tent with strong negative selection to allow cell proliferation.
Although increased signaling through TOR and overexpression
of eIF4E have been associated with transformation and pro-
gression in human cancer (Bjornsti and Houghton, 2004; De
Benedetti and Harris, 1999), the study presented by Avdulov et
al. points to a mechanism in which dysregulation of cap-depen-
dent translation confers resistance to apoptosis under condi-
tions of stress (i.e., serum starvation in vitro or tumor formation
in vivo).
A role for eIF4E in tumorigenesis was also supported by two
recent papers using well-defined genetic models of cancer
(Ruggero et al., 2004; Wendel et al., 2004). However, there are
significant differences between the results of Avdulov et al.
(2004) and those derived from transgenic experiments. In par-
ticular, eIF4E-overexpressing HMECs were not tumorigenic in
mice, which contrasts with recent studies by Ruggero et al.
(2004), where overexpression of eIF4E leads to a high inci-
dence of cancers in mice. Transgenic mice were engineered to
overexpress eIF4E from the β actin promoter. Compared with
wild-type littermates, there was a marked increase in tumorige-
nesis (notably lymphoma, lung adenocarcinoma, angiosarco-
ma, and hepatoma) in transgenic βT-Eif4e mice. It is important
to note that the tumors developed late (beginning at 16 months
of age), suggesting that either eIF4E is an oncogene per se, as
concluded in the study, or alternatively, that dysregulation of
translation initiation results in genomic instability and the accu-
mulation of mutations that in concert with increased translation
result in tumorigenesis. The latter possibility may explain the
discrepancies between the two studies and is supported by
observations that increased expression of eIF4E has been
shown to increase levels of the ribonucleotide reductase 2 sub-
unit, which has been linked with neoplastic transformation in
mammalian cells and increased rates of DNA mutations in yeast
(Abid et al., 1999; Chabes et al., 2003). In addition, nuclear
eIF4E is reported to associate with PML bodies and to mediate
nucleocytoplasmic transport of specific transcripts, which may
contribute to its transforming activity (Topisirovic et al., 2003).
Both Ruggero et al. (2004) and Wendel et al. (2004) report
similar effects of eIF4E overexpression in the context of an Eµ-
Myc transgenic model of B cell lymphoma, where Myc overex-
pression is driven by the immunoglobulin heavy-chain enhancer
transcription element. In this genetic model, modest overex-
pression of murine Eif4e (?2.5-fold over control) markedly
accelerated lymphomagenesis, and was associated with a
decreased rate of apoptosis in tumors. Thus, Eif4e suppresses
Myc-driven apoptosis, leading to more rapid tumor develop-
ment. In the study of Wendel et al. (2004), the effect of Eif4e
overexpression was similar to that induced by constitutive acti-
vation of Akt, i.e., suppression of apoptosis and accelerated
lymphomagenesis. Significantly, both studies show that, in a
p53 heterozygous host, tumors that rapidly develop in Eµ-
Myc/Eif4e mice retain the wild-type p53 allele. Thus, relatively
low-level overexpression of Eif4e, through suppression of apop-
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tosis, abrogates the requirement for loss of p53-induced apop-
tosis for B cell lymphoma development in this model. In addition,
Ruggero et al. (2004) propose that overexpression of Eif4e in
mouse embryonic fibroblasts and Eµ-Myc B cells leads to cellu-
lar senescence, and that Eif4E-driven senescence is abrogated
by Myc. This Eif4e-driven senescence is in contrast to results
obtained by Avdulov et al. in human mammary epithelial cells
(HMECs) and human cancer cells (Dilling et al., 2002), where
overexpression increased growth rate and anchorage-indepen-
dent growth.
Together, these three studies support a causal role for dys-
regulation of cap-dependent translation initiation in both the
genesis of cancer and in its progression. How can this informa-
tion be used to develop improved treatments for human cancer?
The studies of Wendel et al. (2004) shed some light. In their
work, the transgenic Akt/Eµ-Myc and Eµ-Myc/Eif4e B cell lym-
phoma models were used to investigate the effect of Akt or
Eif4e on tumor chemosensitivity. The results are intriguing.
Compared to control lymphomas, which are highly chemosensi-
tive, Akt/Eµ-Myc tumors were resistant to the bifunctional alky-
lating agent cyclophosphamide and the DNA topoisomerase II
poison doxorubicin. Importantly, treatment with the TOR
inhibitor rapamycin restored sensitivity to both cytotoxic agents,
implying TOR function in the Akt-activated antiapoptotic path-
way. As anticipated, overexpression of eIF4E abrogated the
effect of rapamycin, supporting the conjecture that small
changes in the stoichiometry of the suppressor 4E-BP1 and
eIF4E are one determinant of rapamycin sensitivity. In contrast,
rapamycin alone had no significant effect on tumor progression,
leading one to conclude that the effect of Akt in suppressing
Myc-driven apoptosis is independent of TOR. However, this
interpretation should be taken with some caution. In human
cells, the translation of c-Myc is cap-dependent, and is sup-
pressed by rapamycin (Carter et al., 1999; Gera et al., 2003;
Hosoi et al., 1998). Indeed, in human cells in which the Akt path-
way is activated, rapamycin causes a significant shift of c-Myc
RNA from the polysomal fraction to the translationally inactive
pool (Gera et al., 2003). Thus, it would be important to assess
whether, in the Akt/ Eµ-Myc lymphomas, Myc translation is still
TOR-dependent before extrapolating this result to other tumor
models.
Taken together, these three studies support the conclusion
that dysregulation of cap-dependent translation through activa-
tion of the TOR pathway, or overexpression of eIF4E, plays a
role in transformation and tumor progression. Importantly, they
provide insight into the mechanism by which dysregulated
translation suppresses apoptosis, which may counter the pro-
apoptotic activities of p53. These studies further highlight the
potential for development of therapeutic agents that target the
Akt-TOR-eIF4E pathway, which may have significant antitumor
and chemopreventive activities.
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